copper-67

Copper-67 (Cu-67) is a beta-emitting radioisotope with a half-life of approximately 61.8 hours, used primarily as a therapeutic radiopharmaceutical in oncology. Its emission of beta particles enables it to deliver cytotoxic radiation directly to targeted cancer cells, causing DNA damage and cell death while minimizing exposure to healthy tissue due to its short-range emissions[1][5][6]. In addition, Cu-67 emits gamma radiation suitable for imaging via SPECT, allowing real-time monitoring of drug distribution and treatment efficacy[6]. When conjugated to targeting molecules such as monoclonal antibodies or peptides (e.g., bisPSMA for prostate cancer), Cu-67 can be used in targeted radiotherapy for cancers including prostate cancer, neuroendocrine tumors, non-Hodgkin lymphoma, breast cancer, and others[3][5][7][8]. The development of stable chelators has enabled secure attachment of the isotope to these targeting agents[1][7]. Copper isotopes are also notable for their theranostic potential—Cu‑64 is used diagnostically while Cu‑67 provides therapy—enabling personalized treatment strategies within nuclear medicine[2][4].

Other names

copper radioisotope 67Cu radioisotope 67